Business Wire

UT-ICON-HEALTH-&-FITNESS

11.1.2021 12:02:50 CET | Business Wire | Press release

Share
iFit® Introduces Fitness Breakthrough: Personalized and Automatic Heart Rate Training with iFit ActivePulse™

iFit, a global leader in interactive connected fitness technology, today announced the upcoming release of iFit ActivePulse automatic heart rate training. iFit’s cutting edge technology uses complex algorithms so an iFit subscriber’s heart rate controls the treadmill in real time, automatically adjusting the speed and incline to maintain the optimal heart rate zone.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005174/en/

iFit’s game-changing innovation removes the guesswork from heart rate training, by allowing a member’s heart rate to automatically scale and tailor iFit’s vast library of workouts to their individual fitness levels and goals. iFit has applied for patent protection on ActivePulse, which will be available on all iFit-controlled NordicTrack® , ProForm® and Freemotion® treadmills.

Until now, the benefits of heart rate training have hinged on how well a person is able to manually monitor and adjust their effort in order to remain in a particular heart rate zone. In contrast, iFit ActivePulse creates a real-time feedback loop between a user’s measured heart rate and the treadmill’s speed and incline.

iFit ActivePulse heart rate training keeps the user in their optimal zone, while enabling them to accomplish their fitness goals by targeting different heart rate zones.

“ActivePulse lets each iFit customer's heart rate personalize their treadmill workout without the complicated calculations and constant manual adjustments that have long been associated with heart rate training,” said Mark Watterson, President of iFit. “ActivePulse provides a workout that is catered not just to a member; it is catered to that member based on how their heart rate is functioning during the workout.”

Daily variables such as hydration, sleep, and stress have a direct impact on heart rate, therefore the effectiveness of a given workout can vary from one day to the next based on heart rate performance. iFit ActivePulse scales and tailors the intensity of any iFit program to optimize the workout based on their heart rate at that moment—even incorporating advanced algorithms to gradually “learn” their unique behavioral patterns over time.

Heart rate training—the concept of exercising within predetermined ranges (or “zones”) of a user’s maximum heart rate to achieve specific fitness goals—has been used by elite athletes and coaches around the world for more than 30 years. With various heart rate zones corresponding to fitness goals like building endurance, and promoting recovery, heart rate training is widely accepted as the most intelligent way to achieve consistent and measurable progress towards specific fitness goals.

iFit ActivePulse is compatible with leading Bluetooth® heart rate monitors with broadcast functionality, including the iFit SmartBeat™ forearm heart rate monitor, as well as third-party devices from brands including Polar®, Garmin®, Wahoo® and WHOOP®.

Included with all iFit memberships, ActivePulse will be available on all iFit-enabled NordicTrack, ProForm and Freemotion treadmills via an automatic iFit software update in January 2021. The feature will become available for stationary bikes, rowers, and ellipticals from NordicTrack, ProForm and Freemotion soon thereafter.

About iFit

iFit is the patented connected fitness platform that powers NordicTrack, ProForm and Freemotion equipment. ICON, the creator and owner of iFit, pioneered interactive fitness and was issued its first of many patents for its training technology in the early 2000s. Founded with the belief that the majority of consumers would benefit from an interactive, personal training experience at home, iFit’s trainer-led, streaming workouts are now trusted by millions of consumers around the world.

iFit offers workout options for every fitness level and interest—from bodyweight training, boxing, HIIT, yoga, Pilates and more—to connected fitness workouts on NordicTrack home equipment. Patented interactive technology allows iFit Trainers to create workouts for iFit members that automatically adjust the member’s incline, decline, speed and resistance in sync with iFit’s streaming workouts. iFit interactive content is available on NordicTrack, ProForm and Freemotion treadmills, stationary bikes, rowers, ellipticals, strength machines and the iFit app.

ICON Health & Fitness, Inc. is a global health and fitness leader and owner of iFit, NordicTrack, ProForm, Freemotion and other fitness brands. Based in Logan, Utah, the 43-year old company has a multi-decade heritage of innovation and quality. ICON currently holds more than 330 patents, with more than 80 pending, and its products are sold in 116 countries. iFit workouts are streamed in English, Spanish, French and Mandarin Chinese, with more languages planned for 2021.

Join the discussion @iFit , @NordicTrack and @ProForm

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye